经导管房间隔分流器治疗射血分数保留的心力衰竭:REDUCE LAP-HF I 2期随机假手术对照试验
REDUCE LAP-HF I 是一项2期随机双盲假手术对照多中心试验,纳入94例筛选后44例射血分数≥40%的心衰患者,按1:1随机接受房间隔分流器或假手术。1个月时分流器组运动肺毛细血管楔压(PCWP)下降优于假手术组(P=0.028),主要安全终点无差异。
要点
- 对于EF≥40%的心衰患者,房间隔分流器可降低运动时PCWP。
- 1个月时主要不良心脑血管和肾脏事件两组无显著差异。
- 该机制效应能否转化为症状和结局的持续改善尚需进一步评估。
核心结论
- 在EF≥40%的心衰患者中,房间隔分流器治疗可降低运动时的PCWP。
- 这一机制效应能否转化为症状和结局的持续改善尚需进一步评估。
研究设计与样本
- REDUCE LAP-HF I为2期、随机、平行组、盲法多中心试验。
- 纳入纽约心功能III级或可走动IV级、EF≥40%、运动PCWP≥25 mm Hg且PCWP-右心房压差≥5 mm Hg的患者。
- 94例入组,44例符合标准并随机1:1至房间隔分流器组(n=22)或假手术组(n=22)。
- 假手术为股静脉穿刺和心内超声心动图但不置入分流器。
- 主要有效性终点为1个月时运动PCWP,主要安全终点为1个月主要不良心脑血管和肾脏事件。
主要发现
- 1个月时,房间隔分流器组运动PCWP下降大于假手术组(P=0.028,纳入所有运动阶段)。
- 峰值PCWP在治疗组下降3.5±6.4 mm Hg,对照组下降0.5±5.0 mm Hg(P=0.14)。
- 房间隔分流器组无围术期或1个月主要不良心脑血管和肾脏事件,对照组发生1例(肾功能恶化)(P=1.0)。
- 平均年龄70±9岁,女性占50%。
关键数值与推荐
- 纳入标准:纽约心功能III级或可走动IV级、EF≥40%、运动PCWP≥25 mm Hg、PCWP-右心房压差≥5 mm Hg。
- 主要有效性终点:1个月时运动PCWP。
- 主要安全终点:1个月主要不良心脑血管和肾脏事件。
临床怎么用
- 对于EF≥40%的心衰患者,房间隔分流器可考虑用于降低运动PCWP,但需进一步评估临床获益。
- 该装置的安全性和有效性需在更大规模试验中确认。
局限性
- 样本量较小(44例随机),随访仅1个月。
- 峰值PCWP差异未达统计学显著性(P=0.14)。
- 主要终点为血流动力学指标,而非临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In nonrandomized, open-label studies, a transcatheter interatrial shunt device (IASD, Corvia Medical) was associated with lower pulmonary capillary wedge pressure (PCWP), fewer symptoms, and greater quality of life and exercise capacity in patients with heart failure (HF) and midrange or preserved ejection fraction (EF ≥40%). We conducted the first randomized sham-controlled trial to evaluate the IASD in HF with EF ≥40%. METHODS: REDUCE LAP-HF I (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure) was a phase 2, randomized, parallel-group, blinded multicenter trial in patients with New York Heart Association class III or ambulatory class IV HF, EF ≥40%, exercise PCWP ≥25 mm Hg, and PCWP-right atrial pressure gradient ≥5 mm Hg. Participants were randomized (1:1) to the IASD versus a sham procedure (femoral venous access with intracardiac echocardiography but no IASD placement). The participants and investigators assessing the participants during follow-up were blinded to treatment assignment. The primary effectiveness end point was exercise PCWP at 1 month. The primary safety end point was major adverse cardiac, cerebrovascular, and renal events at 1 month. PCWP during exercise was compared between treatment groups using a mixed-effects repeated measures model analysis of covariance that included data from all available stages of exercise. RESULTS: A total of 94 patients were enrolled, of whom 44 met inclusion/exclusion criteria and were randomized to the IASD (n=22) and control (n=22) groups. Mean age was 70±9 years, and 50% were female. At 1 month, the IASD resulted in a greater reduction in PCWP compared with sham control (P=0.028 accounting for all stages of exercise). Peak PCWP decreased by 3.5±6.4 mm Hg in the treatment group versus 0.5±5.0 mm Hg in the control group (P=0.14). There were no peri-procedural or 1-month major adverse cardiac, cerebrovascular, and renal events in the IASD group and 1 event (worsening renal function) in the control group (P=1.0). CONCLUSIONS: In patients with HF and EF ≥40%, IASD treatment reduces PCWP during exercise. Whether this mechanistic effect will translate into sustained improvements in symptoms and outcomes requires further evaluation. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT02600234.
引用
- Feldman T, Mauri L, Kahwash R, et al. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial. Circulation. 2017. PMID: 29142012. doi:10.1161/CIRCULATIONAHA.117.032094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。